|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Ranbaxy Laboratories Limited, a large India-based generic drug company. |
|---|---|
| Transferring Party | The unbranded generic business of Italy-based Allen S.p.A, a division of GlaxoSmithKline, a multi-national pharmaceutical manufacturer. |
| Sector | Biopharmaceuticals |
| Date | March 27, 2006 |
| Analysis "Fast tracks" Ranbaxy’s growth plans in Italy; complementary product portfolios and pipelines. The Italian generic market is one of the fastest growing markets in Europe. As per IMS, December, 2005, its value was approximately $420m, with an annual growth rate of 49%. Ranbaxy has a presence in 21 of the 25 EU countries and is rapidly consolidating its presence in Europe. Terms not disclosed. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |